关键词: 1,2,3,4-tetrahydroisoquinoline Bcl-xL Cancer HPK1 PRMT5 anticancer agents cancer targets

来  源:   DOI:10.1080/13543776.2024.2391288

Abstract:
UNASSIGNED: Cancer is a prominent cause of death globally, triggered by both non-genetic and genetic alterations in genes influenced by various environmental factors. The tetrahydroisoquinoline (THIQ), specifically 1,2,3,4-tetrahydroisoquinoline serves as fundamental element in various alkaloids, prevalent in proximity to quinoline and indole alkaloids.
UNASSIGNED: In this review, the therapeutic applications of THIQ derivatives as an anticancer agent from 2016 to 2024 have been examined. The patents were gathered through comprehensive searches of the Espacenet, Google patent, WIPO, and Sci Finder databases. The therapeutic areas encompassed in the patents include numerous targets of cancer.
UNASSIGNED: THIQ analogues play a crucial role in medicinal chemistry, with many being integral to pharmacological processes and clinical trials. Numerous THIQ compounds have been synthesized for therapeutic purposes, notably in cancer treatment. They show great promise for developing anticancer drugs, demonstrating strong affinity and efficacy against various cancer targets. The creation of multi-target ligands is a compelling avenue for THIQ-based anticancer drug discovery.
摘要:
癌症是全球主要的死亡原因,由各种环境因素影响的基因的非遗传和遗传改变触发。(THIQ),特别是1,2,3,4-四氢呋喃异喹啉是各种生物碱的基本元素,在喹啉和吲哚生物碱附近普遍存在。
在这篇评论中,研究了2016年至2024年THIQ衍生物作为抗癌剂的治疗应用.这些专利是通过对Espacenet的全面搜索收集的,谷歌专利,WIPO,和SciFinder数据库。专利中涵盖的治疗领域包括许多癌症靶标。
THIQ类似物在药物化学中起着至关重要的作用,其中许多是药理学过程和临床试验不可或缺的。已经合成了许多THIQ化合物用于治疗目的,尤其是在癌症治疗中。他们在开发抗癌药物方面显示出巨大的希望,对各种癌症靶标表现出强亲和力和功效。多靶标配体的创建是基于THIQ的抗癌药物发现的引人注目的途径。
公众号